ArticleJournal of cancer research and clinical oncology2025
Silencing PPP2R1A inhibits the progression of gastric cancer cells.
Article in Journal of cancer research and clinical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Expression characteristics, prognostic value, and immune-related analysis of PPP2R1A in lung adenocarcinoma.Frontiers in immunology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundProtein phosphatase 2 regulatory subunit A alpha (PPP2R1A) is the most common scaffold protein in the PP2A complex and has known tumor-suppressive functions. However, its role in gastric cancer (GC) is still unclear. This study aims to elucidate the potential regulatory role of PPP2R1A in the biological functions of GC.
methodsThe mutation status and expression levels of PPP2R1A in GC were assessed through bioinformatics analysis, the correlation between PPP2R1A levels and patient survival rates was examined, and its potential functional network was analyzed. Stable AGS and MGC803 cell lines were set up for overexpressing and silencing PPP2R1A. The effects on cell proliferation, migration, invasion, and apoptosis were assessed through CCK-8 assays, scratch assays, Transwell assays, and flow cytometry.
resultsThe expression of PPP2R1A is significantly elevated in GC samples (P < 0.001) and is not caused by mutations in PPP2R1A (P > 0.05). Patients with high levels of PPP2R1A have a poorer 5-year survival rate (P < 0.001). Silencing PPP2R1A significantly inhibits the proliferation, migration, and invasion of GC cells while promoting apoptosis (P < 0.01). In contrast, overexpression of PPP2R1A does not have a significant impact on these cellular functions (P > 0.05).
conclusionPPP2R1A has potential oncogenic properties in the progression of GC, and knocking down the expression of PPP2R1A can inhibit the tumor progression of GC cells. This suggests that PPP2R1A may serve as a potential prognostic marker and therapeutic target for GC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.